Market and Service

   More than 40 million in the US population are afflicted with IgE-mediated allergic diseases as manifested in allergic asthma, rhinitis, food allergy and anaphylactic shock. Twenty million are afflicted with allergic asthma in the US alone.

   Revenues of the prescribed small molecule drugs in treating allergic asthma and rhinitis exceeds twenty billion USD. The annual growth of the market is more than 10%. Xolair is the only approved anti-asthma large molecule drug in the biological category. This drug is in the form of a monoclonal antibody produced by Genentech. In 2006, the annual sale exceeded 320 million. The medical reimbursement cost restricted its distribution to moderate to severe asthmatic patients, and the side effect of anaphylaxis has caused an FDA black-box warning to this group of prescribed users.

   The next generation of IgE therapeutics in the biological category developed by IGE Company targets at the upstream to lower levels of IgE levels. The drugs may elicit protective cellular and humoral immune response in the recipients to lower IgE levels. Due to the technological advantage and the lower cost, the products may serve all patients afflicted with allergic asthma and rhinitis.